Method for treating a subterranean formation

Patent metadata

Field	Value
Publication number	US-2016289544-A1
Application number	US-201514676162-A
Country	US
Kind code	A1
Filing date	Apr 1, 2015
Priority date	Apr 1, 2015
Publication date	Oct 6, 2016
Grant date	—

Abstract

A method of treating a subterranean formation including combining an aqueous fluid, a biomaterial, an enzyme, and a deactivator to form a treatment fluid; and introducing the treatment fluid into the subterranean formation. A method is also disclosed for treating a subterranean formation by preparing a treatment fluid containing an aqueous fluid that contains bacterial and/or fungal cells that produce an enzyme that degrades the biomaterial, a biomaterial, and a deactivator; controlling degradation of the biomaterial by adding an effective amount of the deactivator to the aqueous fluid prior to the preparation of the treatment fluid; and introducing the treatment fluid into the subterranean formation. In the methods, the enzyme degrades the biomaterial and the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial.

First claim

What is claimed is:

1 . A method for treating a subterranean formation, the method comprising:
combining an aqueous fluid, a biomaterial, an enzyme, and a deactivator to form a treatment fluid; and introducing the treatment fluid into the subterranean formation; wherein: the enzyme degrades the biomaterial; and the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial.

2 . The method according to claim 1 , wherein the deactivator comprises at least one structure selected from a group consisting of a phenol, naphthol, dimethoxybenzene, trimethoxybenzene, and a structure represented by Formula (1):

where:
R7 represents an alkyl group having about 1 to about 5 atoms optionally including one or more heteroatoms; and
R3, R4, R5, and R6 each independently represents a hydrogen atom, a hydroxyl group, an alkyl group, an alkene group, an ester, a carboxylic acid, an alcohol, an aldehyde, a ketone, an aryl, an aryloxy, cycloalkyl, a carbonyl, or an amino group.

3 . The method according to claim 1 , wherein at least a portion of the enzyme is produced by bacterial and/or fungal cells present in the aqueous fluid.

4 . The method according to claim 1 , further comprising adjusting a viscosity of the treatment fluid to be a viscosity in a range of from about 10 cP to about 5,000 cP before introducing the treatment fluid into the subterranean formation.

5 . The method according to claim 4 , wherein adjusting the viscosity of the treatment fluid comprises increasing an amount of the deactivator in the treatment fluid.

6 . The method according to claim 5 , wherein the amount of the deactivator in the treatment fluid is increased to an amount in a range of from about 0.005 g/L to about 15 g/L.

7 . The method according to claim 1 , wherein the enzyme is selected from a group consisting of mannanase, glucosidase, cellulase, amylase, hydrolase, and glucanase.

8 . The method according to claim 2 , wherein the deactivator is selected from a group consisting of methoxyphenol, ethoxy phenol, propoxyphenol, butoxyphenol, dimethoxyphenol, trimethyoxyphenol, dihydroxy-methoxybenzene, dihydroxy-dimethoxybenzene, trihydroxyphenol, methoxy-methylphenol, allyl methoxyphenol, allyl dimethoxyphenol, rutin hydrate, epicatechin, 5-(3, 4, 5-trihydroxyphenyl)-γ-valerolactone, gallic acid, tannic acid, vanillic acid, salicyclic acid, guaiacol, polyphenon 60, liginsulfonate, hesperidin, epigallocatechin gallate, 1-amino-2-naphthol, 2-amino-1-naphthol, 3-amino-2-naphthol, 4-amino-1-naphthol, 8-amino-1-naphthol, 5-amino-1-naphthol, 1,2-dimethoxybenzene, 1,3-dimethoxybenzene, 1,2,3-trimethoxybenzene, 1,2,4-trimethoxybenzene, 1,2,5-trimethoxybenzene, 1,2,6-trimethoxybenzene, and 1,3,5-trimethoxybenzene, 1,3-benzodioxole, benzo-1,4,-dioxane, 2,3-dihydro-1,4,-benzodioxin-5-ol, 5-methoxy-1,3-benzodioxole, 5,6-dihydroxy-1,3-benzodioxole, sesamol, 5-methyl-1,3-benzodioxole, sesamin, piperonyl alcohol, piperonal, and 3,4-methylenedioxy aniline, 1,8-dihydroxynaphthalene, 1,5-dihydroxynaphthalene, 2,3-dihydroxynaphthalene, 2,7-dihydroxynaphthalene, 1,7-dihydroxynaphthalene, and 2,6-dihydroxynaphthalene.

9 . The method according to claim 1 , wherein the biomaterial is selected from a group consisting of guar gum, locust bean gum, tara gum, honey locust gum, tamarind gum, karaya gum, arabic gum, ghatti gum, tragacanth gum, carrageenan, succinoglycan, xanthan, diutan, alginate, hydroxylethyl guar. hydroxypropyl guar, carboxymethylhydroxypropyl guar, carboxymethyl cellulose, carboxyethyl cellulose, carboxymethyl guar, carboxymethylhydroxyethyl cellulose, and combinations thereof.

10 . The method according to claim 3 , wherein prior to forming the treatment fluid, the method further comprises measuring an amount of the bacterial and/or fungal cells in the aqueous fluid.

11 . The method according to claim 10 , further comprising:
determining an effective amount of the deactivator for controlling a viscosity of the treatment fluid to be in a range of from about 10 cP to about 5,000 cP based on the measurement of the amount of bacterial and/or fungal cells present in the aqueous fluid; and combining the effective amount of the deactivator with the aqueous fluid, the biomaterial, and the enzyme.

12 . The method according to claim 1 , wherein the treatment fluid further comprises a crosslinking agent.

13 . The method according to claim 1 , wherein the treatment fluid further comprises proppant particles.

14 . A method for treating a subterranean formation, the method comprising:
preparing a treatment fluid comprising an aqueous fluid, a biomaterial, and a deactivator; controlling degradation of the biomaterial by adding an effective amount of the deactivator to the aqueous fluid prior to the preparation of the treatment fluid; and introducing the treatment fluid into the subterranean formation; wherein: the aqueous fluid comprises bacterial and/or fungal cells that produce an enzyme that degrades the biomaterial; and the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial.

15 . The method according to claim 14 , wherein the deactivator comprises at least one structure selected from a group consisting of a phenol, naphthol, dimethoxybenzene, trimethoxybenzene, and a structure represented by Formula (1):

where:
R7 represents an alkyl group having about 1 to about 5 atoms optionally including one or more heteroatoms; and
R3, R4, R5, and R6 each independently represents a hydrogen atom, a hydroxyl group, an alkyl group, an alkene group, an ester, a carboxylic acid, an alcohol, an aldehyde, a ketone, an aryl, an aryloxy, cycloalkyl, a carbonyl, or an amino group.

16 . The method according to claim 14 , wherein a viscosity of the treatment fluid is in a range of from about 10 cP to about 5,000 cP before introducing the treatment fluid into the subterranean formation.

17 . The method according to claim 14 , wherein the enzyme is selected from a group consisting of mannanase, glucosidase, cellulase, amylase, hydrolase, and glucanase.

18 . The method according to claim 14 , wherein the effective amount of the deactivator is an amount in a range of from about 0.005 g/L to about 15 g/L.

19 . The method according to claim 14 , wherein the deactivator is selected from a group consisting of methoxyphenol, ethoxy phenol, propoxyphenol, butoxyphenol, dimethoxyphenol, trimethyoxyphenol, dihydroxy-methoxybenzene, dihydroxy-dimethoxybenzene, trihydroxyphenol, methoxy-methylphenol, allyl methoxyphenol, allyl dimethoxyphenol, rutin hydrate, epicatechin, 5-(3, 4, 5-trihydroxyphenyl)-γ-valerolactone, gallic acid, tannic acid, vanillic acid, salicyclic acid, guaiacol, polyphenon 60, liginsulfonate, hesperidin, epigallocatechin gallate, 1-amino-2-naphthol, 2-amino-1-naphthol, 3-amino-2-naphthol, 4-amino-1-naphthol, 8-amino-1-naphthol, 5-amino-1-naphthol, 1,2-dimethoxybenzene, 1,3-dimethoxybenzene, 1,2,3-trimethoxybenzene, 1,2,4-trimethoxybenzene, 1,2,5-trimethoxybenzene, 1,2,6-trimethoxybenzene, and 1,3,5-trimethoxybenzene, 1,3-benzodioxole, benzo-1,4,-dioxane, 2,3-dihydro-1,4,-benzodioxin-5-ol, 5-methoxy-1,3-benzodioxole, 5,6-dihydroxy-1,3-benzodioxole, sesamol, 5-methyl-1,3-benzodioxole, sesamin, piperonyl alcohol, piperonal, and 3,4-methylened

Assignees

• Schlumberger Technology Corp

Inventors

• Lee Wingki
• Makarychev-Mikhailov Sergey
• Hutchins Richard Donald
• Meza Camille

Classifications

• C09K8/905

  Biopolymers · CPC title

• C09K8/80

  Compositions for reinforcing fractures, e.g. compositions of proppants used to keep the fractures open · CPC title

• C09K8/68 Primary

  containing organic compounds · CPC title

• C09K8/887

  containing cross-linking agents · CPC title

• C09K8/685

  containing cross-linking agents · CPC title